Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 6Completed 4Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Parkinson Disease 4, Autosomal Dominant Lewy Body 21Breast Neoplasms 17Neoplasms 16Multiple Myeloma 15Leukemia, Myeloid, Acute 15Recurrence 10Colorectal Neoplasms 10Myelodysplastic Syndromes 9Lymphoma, Non-Hodgkin 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Lymphoma, Follicular 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Stomach Neoplasms 6Ovarian Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Uterine Cervical Neoplasms 5Purpura, Thrombocytopenic, Idiopathic 5Neoplasm Metastasis 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Graft vs Host Disease 5Esophageal Neoplasms 5Bronchiolitis Obliterans Syndrome 5Adenocarcinoma 5

Interventions

enfortumab vedotin 2vinflunine 1sacituzumab govitecan 1avelumab 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has announcements × Urinary Bladder Neoplasms × Clear all
NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03219333 2024-08-27

EV-201

Astellas Pharma Inc

Phase 2 Completed
219 enrolled 32 charts 2 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT02603432 2024-03-27

JAVELIN Bladder 100

Pfizer

Phase 3 Completed
700 enrolled 35 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡